Eric M. Verdin

Eric M. Verdin is the fifth President and Chief Executive Officer of the Buck Institute for Research on Aging.[1][2] A native of Belgium, Verdin received his Doctorate of Medicine (MD) from the University of Liege and additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a Professor of Medicine at University of California, San Francisco.

Verdin’s laboratory focuses on the role of epigenetic regulators in the aging process. His laboratory was first to clone a family of enzymes, called HDACs, which regulate histone acetylation. Verdin studies how metabolism, diet and small molecules regulate the activity of HDACs and Sirtuins and thereby the aging process and its associated diseases, including Alzheimer’s. He has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist (top 1%) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation.[3] He is an elected member of several scientific organizations including the American Association for the Advancement of Science, the American Society for Clinical Investigation and the Association of American Physicians. He also serves on the Advisory Council of NIDA at the National Institutes of Health.

Selected publications

  • Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015 Dec 4; 350(6265):1208-13. doi:10.1126/science.aac4854. Review. PMID 26785480.[4]
  • Verdin E, Ott M. 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol. 2015 Apr; 16(4):258-64. doi:10.1038/nrm3931. PMID 25549891.[5]
  • Gut P, Verdin E. The nexus of chromatin regulation and intermediary metabolism. Nature. 2013 Oct 24; 502(7472):489-98. doi:10.1038/nature12752. Review. PMID 24153302.[6]
  • Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013 Jan 11; 339(6116):211-4. doi:10.1126/science.1227166. PMID 23223453; PMC 3735349.[7]
  • Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, Stančáková A, Goetzman E, Lam MM, Schwer B, Stevens RD, Muehlbauer MJ, Kakar S, Bass NM, Kuusisto J, Laakso M, Alt FW, Newgard CB, Farese RV Jr, Kahn CR, Verdin E. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell. 2011 Oct 21; 44(2):177-90. doi:10.1016/j.molcel.2011.07.019. PMID 21856199; PMC 3563434.[8]
  • Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman NB, Bain JR, Newgard CB, Farese RV Jr, Alt FW, Kahn CR, Verdin E. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010 Mar 4; 464(7285):121-5. doi:10.1038/nature08778. PMID 20203611; PMC 2841477.[9]

References

  1. ↑ "Buck Institute for Research on Aging names new CEO, announces $10M board donation". Retrieved 2017-03-06.
  2. ↑ "Novato's Buck Institute hires new CEO, gets $10M gift". The North Bay Business Journal. 2016-11-25. Retrieved 2017-03-06.
  3. ↑ "Role of a SIRT3, a Sir2-related Mitochondrial Protein Deacetylase, in Aging | The Lawrence Ellison Foundation". www.ellisonfoundation.org. Retrieved 2017-03-07.
  4. ↑ Verdin, Eric (2015-12-04). "NAD+ in aging, metabolism, and neurodegeneration". Science. 350 (6265): 1208–1213. doi:10.1126/science.aac4854. ISSN 0036-8075. PMID 26785480.
  5. ↑ Verdin, Eric; Ott, Melanie. "50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond". Nature Reviews. Molecular Cell Biology. 16 (4): 258–264. doi:10.1038/nrm3931. ISSN 1471-0080. PMID 25549891.
  6. ↑ Gut, Philipp; Verdin, Eric (2013-10-24). "The nexus of chromatin regulation and intermediary metabolism". Nature. 502 (7472): 489–498. doi:10.1038/nature12752. ISSN 1476-4687. PMID 24153302.
  7. ↑ Shimazu, Tadahiro; Hirschey, Matthew D.; Newman, John; He, Wenjuan; Shirakawa, Kotaro; Le Moan, Natacha; Grueter, Carrie A.; Lim, Hyungwook; Saunders, Laura R. (2013-01-11). "Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor". Science. 339 (6116): 211–214. doi:10.1126/science.1227166. ISSN 0036-8075. PMC 3735349. PMID 23223453.
  8. ↑ Hirschey, Matthew D.; Shimazu, Tadahiro; Jing, Enxuan; Grueter, Carrie A.; Collins, Amy M.; Aouizerat, Bradley; Stančáková, Alena; Goetzman, Eric; Lam, Maggie M. (2011-10-21). "SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome". Molecular Cell. 44 (2): 177–190. doi:10.1016/j.molcel.2011.07.019. ISSN 1097-4164. PMC 3563434. PMID 21856199.
  9. ↑ Hirschey, Matthew D.; Shimazu, Tadahiro; Goetzman, Eric; Jing, Enxuan; Schwer, Bjoern; Lombard, David B.; Grueter, Carrie A.; Harris, Charles; Biddinger, Sudha (2010-03-04). "SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation". Nature. 464 (7285): 121–125. doi:10.1038/nature08778. ISSN 1476-4687. PMC 2841477. PMID 20203611.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.